|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||47.50 - 49.00|
|52 Week Range||36.26 - 56.34|
|Beta (3Y Monthly)||1.50|
|PE Ratio (TTM)||260.16|
|Earnings Date||Aug 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||54.36|
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.
MORRISVILLE, N.C., July 08, 2019 -- Syneos HealthTM (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research.
Read the beginning of this article here. The most valuable position in Hawk Ridge Capital Management’s 13F portfolio was in frontdoor, inc. (NASDAQ:FTDR) worth $31.04 million, counting 901,855 shares, amassing 6.54% of its equity portfolio. Frontdoor is one of the biggest US providers of home service plans with a large network of pre-qualified contractors. It […]
Syneos Health, Inc. (NASDAQ:SYNH), which is in the life sciences business, and is based in United States, saw a...
Low-cost index funds make it easy to achieve average market returns. But across the board there are plenty of stocks...
MORRISVILLE, N.C., June 24, 2019 -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today introduced FSP 360, an evolved FSP.
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
Syneos Health Inc NASDAQ/NGS:SYNHView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for SYNH with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding SYNH totaled $324 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The 11th annual Dealmakers’ Intentions Study from Syneos Health Consulting, an industry-leading biopharmaceutical management consulting firm, indicates that there will be an acceleration in dealmaking across all deal types. The 2019 survey results indicate that buyers appear more willing to accept risk associated with opportunities in the early development and rare disease categories. The study, released during a Super Session at the BIO International Convention in Philadelphia, provides a review of biopharmaceutical dealmakers’ intentions around licensing and acquisitions for the next 12 months, identifying areas of greatest opportunities for buyers and sellers.
MORRISVILLE, N.C., May 31, 2019 -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Patrick.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
MORRISVILLE, N.C., May 21, 2019 -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research.
Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.
Syneos Health™ (SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Tara Fitzgerald, President, Clinical Development Services, and Kari L. Delahunty, Senior Vice President, Corporate Strategy, will be honored by the Healthcare Businesswomen’s Association (HBA). The honorees will be recognized today at the 30th Annual HBA Woman of the Year (WOTY) luncheon in New York City for their leadership within the healthcare industry. “We’re thrilled to see the industry take notice of Tara and Kari, leaders who exemplify the inclusive and collaborative leadership style that we cultivate at Syneos Health,” said Alistair Macdonald, Chief Executive Officer, Syneos Health.
Syneos Health (SYNH) delivered earnings and revenue surprises of -1.67% and 0.02%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Morrisville, North Carolina-based company said it had a loss of 29 cents per share. Earnings, adjusted for one-time gains and costs, were 59 cents per share. The results fell short of Wall Street expectations. ...
Highlights GAAP revenue of $1.12 billion for the three months ended March 31, 2019.Net new business awards of $5.52 billion for the trailing twelve months (TTM) ended March 31,.
SAN DIEGO, CA / ACCESSWIRE / May 7, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in NASDAQ: SYNH shares. Investors, who purchased shares of Syneos ...
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.